Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report.
| Title: | Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report. |
|---|---|
| Authors: | Todberg T; Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.; Copenhagen Research Group for Inflammatory Skin (CORGIS), Hellerup, Denmark.; Loft ND; Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.; Copenhagen Research Group for Inflammatory Skin (CORGIS), Hellerup, Denmark.; Zachariae C; Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.; Copenhagen Research Group for Inflammatory Skin (CORGIS), Hellerup, Denmark. |
| Source: | Case reports in dermatology [Case Rep Dermatol] 2020 Aug 18; Vol. 12 (2), pp. 150-154. Date of Electronic Publication: 2020 Aug 18 (Print Publication: 2020). |
| Publication Type: | Case Reports; Journal Article |
| Language: | English |
| Journal Info: | Publisher: Karger Country of Publication: Switzerland NLM ID: 101517685 Publication Model: eCollection Cited Medium: Print ISSN: 1662-6567 (Print) Linking ISSN: 16626567 NLM ISO Abbreviation: Case Rep Dermatol Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Basel : Karger |
| Abstract: | Alopecia areata (AA) is the most common immune-mediated hair loss disorder with a life-time prevalence of 2%. The pathogenesis of AA is not completely understood, but interferon gamma (INF-γ) and Janus kinases (JAK) may play a key role. Here, we present a case involving a male patient with psoriasis and psoriatic arthritis, who exhibited a rapid hair loss, diagnosed as AA, during ciclosporin treatment. As ciclosporin was unable to control his psoriasis, the treatment was changed to methotrexate injections, but the hair loss progressed into alopecia universalis. During treatment with the oral JAK inhibitor tofacitinib, the patient presented an almost complete hair remission on the scalp and partly on the eyebrows, eyelashes, beard, and chest. Furthermore, the patient experienced no joint complaints and his psoriasis was improved. Based on these findings, JAK inhibitors may be an optional treatment in complicated cases involving both rheumatological and dermatological diseases.; (Copyright © 2020 by S. Karger AG, Basel.) |
| Competing Interests: | Dr. Todberg has served as investigator for Novartis and LEO Pharma. Dr. Loft has been an honorary speaker for Eli Lilly. Dr. Zachariae has consulting relationships and/or is an investigator and/or received grants or honoraria from Eli Lilly and Company, Janssen Cilag, Novartis Pharmaceutical Corp., AbbVie, Takeda, Amgen, MSD, LEO Pharmaceuticals, Boehringer-Ingelheim, Almirall, and Regeneron. |
| References: | J Am Acad Dermatol. 2019 Jan;80(1):120-127.e2. (PMID: 30003990); Clin Rev Allergy Immunol. 2018 Feb;54(1):102-113. (PMID: 29349534); Int J Dermatol. 2017 Aug;56(8):801-810. (PMID: 28378336); J Am Acad Dermatol. 2017 Apr;76(4):736-744. (PMID: 28139263); Dermatol Ther. 2019 May;32(3):e12844. (PMID: 30693634); N Engl J Med. 2012 Apr 19;366(16):1515-25. (PMID: 22512484) |
| Contributed Indexing: | Keywords: Alopecia areata; Alopecia universalis; Psoriasis; Psoriasis treatment; Psoriatic arthritis |
| Entry Date(s): | Date Created: 20201001 Latest Revision: 20201002 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC7506247 |
| DOI: | 10.1159/000508782 |
| PMID: | 32999651 |
| Database: | MEDLINE |
Case Reports; Journal Article